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A Monomeric Variant of Insulin Degrading Enzyme (IDE)
Loses Its Regulatory Properties
Eun Suk Song, David W. Rodgers, Louis B. Hersh*
Department of Molecular and Cellular Biochemistry and the Center for Structural Biology, University of Kentucky, Lexington, Kentucky, United States of America

Abstract
Background: Insulin degrading enzyme (IDE) is a key enzyme in the metabolism of both insulin and amyloid beta peptides.
IDE is unique in that it is subject to allosteric activation which is hypothesized to occur through an oligomeric structuture.
Methodology/Principal Findings: IDE is known to exist as an equilibrium mixture of monomers, dimers, and higher
oligomers, with the dimer being the predominant form. Based on the crystal structure of IDE we deleted the putative dimer
interface in the C-terminal region, which resulted in a monomeric variant. Monomeric IDE retained enzymatic activity,
however instead of the allosteric behavior seen with wild type enzyme it displayed Michaelis-Menten kinetic behavior. With
the substrate Abz-GGFLRKHGQ-EDDnp, monomeric IDE retained ,25% of the wild type activity. In contrast with the larger
peptide substrates b-endorphin and amyloid b peptide 1–40, monomeric IDE retained only 1 to 0.25% of wild type activity.
Unlike wild type IDE neither bradykinin nor dynorphin B-9 activated the monomeric variant of the enzyme. Similarly,
monomeric IDE was not activated by polyphosphates under conditions in which the activity of wild type enzyme was
increased more than 50 fold.
Conclusions/Significance: These findings serve to establish the dimer interface in IDE and demonstrate the requirement
for an oligomeric form of the enzyme for its regulatory properties. The data support a mechanism where the binding of
activators to oligomeric IDE induces a conformational change that cannot occur in the monomeric variant. Since a
conformational change from a closed to a more open structure is likely the rate-determining step in the IDE reaction, the
subunit induced conformational change likely shifts the structure of the oligomeric enzyme to a more open
conformation.
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produced by small peptides (heterotrophic activation). In addition
we reported that polyphosphates such as ATP and triphosphate act
as non-substrate heterotrophic activators, binding at a site distinct
from the active site and distinct from the peptide activation
site [12].
Recently the structures of IDE both liganded and unliganded
were determined by Tang and co-workers [13–15]. These
structures show that larger peptides make extended binding
interactions at both the active site and at a distal site. We have
recently determined the structure of rat IDE and found that this
distal binding site serves as the site in which small peptide
activators bind (Nicholas Noinaj, Sonia K. Bhasin, Eun Suk Song,
Kirsten Scoggin, Louis B. Hersh, and David W. Rodgers,
manuscript in preparation).
IDE exists as a mixture of monomers, dimers, and tetramers
with the dimer the predominant species [11]. From the IDE
structure of Shen et al [13] and confirmed in our IDE structure an
interface between the two monomeric units involving elements
from domains 3 and 4 of the four-domain protein was identified.
We have taken advantage of this structural data to generate a
monomeric variant of IDE. Studies on this monomeric IDE

Introduction
Insulin-degrading enzyme (IDE) also known as insulysin, is a
zinc metalloprotease first described based on its ability to cleave
insulin [1–3]. Mutations in IDE are linked to a type II diabetic
phenotype in the GK rat [4]. In addition IDE has been shown to
play a key role in Alzheimer’s disease in that it is one of the major
enzymes responsible for amyloid b peptide (Ab) clearance in the
brain. Studies from this [5] and other laboratories [6] have shown
that mice lacking IDE activity through gene disruption accumulate
Ab in the brain in a gene dose dependent manner. A number of
studies have linked the IDE gene to both type 2 diabetes [7,8] and
AD [9,10] although in the latter case a genetic association has yet
to be firmly established.
We first reported that IDE is unique among the zinc
metalloproteases in that it exhibits allosteric kinetic behavior
[11]. The reaction of IDE with the internally quenched fluorogenic
substrate 2-aminobenzyl-glycyl-glycyl-phenylalanyl-leucyl-arginyllysyl-histidyl-glycyl-asparaginyl-ethylenediamine-2,4-dinitrophenol
(Abz-GGFLRKHGQ-EDDnp) was shown to exhibit both substrate induced (homotrophic) activation as well as activation
PLoS ONE | www.plosone.org
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support our previous hypothesis [11] that an oligomeric form of
IDE is required for allosteric activation.

examined our crystal structure of rIDE for a possible dimerization
domain and found that molecular packing within the rIDE crystal
lattice consistent with the presence of a dimer interface at the Cterminal region of the enzyme. This possibility is supported by the
conservation of this interface in the crystals of hIDE [13] even
though the human enzyme crystallizes in a different form. The
proposed dimer interface buries about 1,400 Å2 of accessible

Results
IDE is known to exist in a monomer-dimer-tetramer equilibrium with the dimer being the predominant form [11]. We

Figure 1. Proposed dimer of IDE. (A) Two orthogonal views of rIDE monomers from the crystal lattice are shown with elements making up the
dimer interface highlighted in red for the top subunit. IDE is composed of four structurally related domains. Those domains are numbered in the top
subunit in the left panel, and the N and C termini are indicated for the top subunit in the right panel. The C terminal region of IDE deleted in the
rIDEDC construct intended to destabilize the dimer interface is highlighted in blue for the lower monomers in both panels. (B) Close up of the dimer
interface showing the region deleted in the rIDEDC construct. Deleted residues 1002–1014 are shown in a stick representation with sheet-like
hydrogen bonds across the interface at Leu1004 indicated by dashed lines.
doi:10.1371/journal.pone.0009719.g001
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Figure 2. Comparison of the molecular weight forms of wild type IDE and IDEDC on a Superdex S200 gel filtration column. Wild type
IDE or the IDEDC variant was chromatographed on a Pharmacia Superdex S200 gel filtration column in 20 mM potassium phosphate buffer, pH 7.4.
One ml of protein at 0.5 mg/ml was loaded and the column developed at a flow rate of 0.4 ml/min. Fractions were collected and assayed for IDE
activity using Abz-GGFLRKHGQ-EDDnp as the substrate.
doi:10.1371/journal.pone.0009719.g002

tetrameric, dimeric, and monomeric species, with the dimer being
the predominant form as expected. In contrast chromatography of
rIDEDC on the same column at the same protein concentration
showed a single monomeric species.
The kinetics of the rIDEDC reaction was compared to wild type
rIDE using the fluorogenic substrate Abz-GGFLRKHGQEDDnp. rIDEDC retained enzymatic activity, however it no
longer exhibited the sigmoidal kinetics seen with wild type rIDE,
Figure 3. The kinetic constants, summarized in Table 1, show that
rIDEDC exhibits about 25% of the kcat of wild type rIDE, but has a
lower substrate KM. In contrast to wild type rIDE, where the
reaction is cooperative with a Hill coefficient of 2, rIDEDC exhibits
classical Michaelis-Menten kinetics with a Hill coefficient of ,1.
We next determined whether rIDEDC retained the ability to
degrade larger physiological substrates by comparing its reaction
with b-endorphin and amyloid b peptide 1–40 (Ab1–40) to the
reaction of wild type rIDE. At a fixed concentration of 10 mM
substrate rIDEDC cleaved these larger peptide substrates at about 1
to 0.25% the rate of wild type rIDE. With Ab1–40 we observed

surface area and involves elements from domains 3 and 4 of the
four structurally related domains that make up the enzyme,
Figure 1. A key set of contacts occurs between regions near the Cterminus of each monomer, residues 1002–1006, which make nonpolar and hydrogen bond interactions across the interface.
rIDE has only 13 residues C terminal to this interaction region,
and only eight (to residue 1014) are seen in the crystal structure,
which suggests that the C-terminal region of IDE could be
removed without greatly compromising the stability of the enzyme.
Such a deletion should destabilize the dimer interface sufficiently
to make monomeric IDE the predominant form in solution. To
test this hypothesis and to study the properties of monomeric IDE
we generated a mutant in which residues 1002 to 1019 were
deleted yielding rIDEDC. This mutant, as well as wild type rIDE,
were expressed in insect cells as hexahistidine fusion proteins and
purified by nickel affinity chromatography.
We demonstrated that rIDEDC is monomeric by molecular sieve
chromatography. As shown in Figure 2, chromatography of wild
type rIDE on a Superdex S200 column revealed the presence of

Figure 3. Comparison of the kinetics of IDEDC and wild type IDE. Reactions were conducted in 50 mM Tris-HCl, pH 7.4 using either 0.25 mg of
wild type IDE (left) or 1.25 mg of IDEDC (right) and Abz-GGFLRKHGQ-EDDnp as the variable substrate. Data were fit to either a hyperbolic or sigmoidal
response curve as described in Methods with the values and errors included in Table 1.
doi:10.1371/journal.pone.0009719.g003
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the shift in fluorescence maximum is notably less than observed
with wild-type IDE.

Table 1. Comparison of kinetic constants for IDE and
monomeric IDE.

Discussion
kcat (min21)

IDE

IDEDC

2.6260.26

0.6760.02

K0.5 or Km (mM)

21.563.7

6.660.2

Hill coefficient

2.060.3

1.160.1

Contacts in crystals of IDE suggest that the dimer interface is
formed by elements of the two C-terminal domains, including a
sheet-like contact formed by a terminal b strand. Thus by deleting
18 residues from the C terminus, we anticipated that the
intermolecular contacts would be sufficiently weakened that only
monomers would be stable. This was indeed the case as evidenced
by the finding of only monomeric rIDE in the deletion mutant
preparation.
The monomeric rIDE variant exhibits 25% of the catalytic
activity of wild type rIDE and no longer exhibits substrate induced
homotrophic activation with Abz-GGFLRKHGQ-EDDnp. Substrate induced cooperativity or homotrophic activation, likely
results from binding of the substrate at a site distinct from the
catalytic site that is part of an extended substrate-binding site
(Nicholas Noinaj, Sonia K. Bhasin, Eun Suk Song, Kirsten
Scoggin, Louis B. Hersh, and David W. Rodgers, manuscript in
preparation). Binding at this region of the extended substrate
binding site is suggested to produce a conformational change in
the adjacent subunit. Thus the absence of substrate induced
cooperativity as shown by change from a sigmoidal substrate
versus velocity response seen with wild type IDE to a hyperbolic
response seen in monomeric IDE can be explained by the loss of
subunit-subunit interactions.
In contrast to the relatively small decrease in kcat observed with
Abz-GGFLRKHGQ-EDDnp as substrate, the monomeric rIDE
variant exhibits a 100 to 200-fold decrease in the rate of cleavage
of the larger physiological peptides b-endorphin and amyloid b
peptide. Larger peptides like b-endorphin and amyloid b peptide
traverse the protein and bind both at the active site as well as at a
distal site [13]. Since a portion of amyloid b peptide (and likely bendorphin) occupies the distal site we suggest these substrates ‘‘selfactivate’’ producing the same or similar conformational change in
the adjacent subunit and are thus insensitive to heterotrophic
activation.
The crystallographic studies of Tang and coworkers [13] show
that IDE totally engulfs the bound peptide in the Michaelis complex,
with no room for products to dissociate. Thus the rate-determining
step must involve a conformational change that opens the enzyme to
permit product dissociation. The increase in kcat produced by
activators with small synthetic substrates would therefore involve an
increase in the rate of enzyme opening produced by the binding of
substrate to one subunit and transmitting a conformational change
to the adjacent subunit. Clearly this cannot occur in monomeric
IDE, leading to a decrease in kcat.
With the larger substrates b-endorphin and amyloid b peptide
the extended binding interactions would be expected to make the
conformational change needed for product release energetically
more difficult than with small substrates. We suggest that one
possibility is that hydrolysis of the substrate in the active site of one
oligomeric subunit produces the driving force that leads to a
conformational change transmitted to the adjacent subunit. This
conformational change increases the rate of enzyme opening and
product release. In the monomeric enzyme the absence of an
induced conformational change would be a major contributing
factor to the slow rate of cleavage of physiological peptide
substrates. An alternative hypothesis is that substrate binding in
itself is sufficient to translate a conformation change from one
monomeric unit to the other which shifts the equilibrium of one
subunit to the open conformation and promotes product release.

Kinetic constants were derived by fitting the data from two experiments similar
to that shown in figure 3 to a sigmoidal or hyperbolic substrate versus velocity
response curve as described in Methods.
doi:10.1371/journal.pone.0009719.t001

peptide products that appeared with wild type IDE, but were
absent from the rIDEDC cleavage, and unique products that
appeared only in the rIDEDC cleavage. As shown in figure 4 (top),
those products absent in the rIDEDC cleavage of Ab1–40 were
identified as Ab1–18 (cleavage at a Val-Phe bond) and Ab1–13
(cleavage at a His-His bond), while products unique to the rIDEDC
cleavage of Ab1–40 were Ab1–17 (unique cleavage at a Leu-Val
bond), Ab14–22 (unique cleavage at a Glu-Asp bond), Ab19–33
(unique cleavage at a Gly-Leu bond), and Ab26–40 (unique
cleavage at Ser-Asn bond).
Similarly we identified two additional cleavage sites in bendorphin with rIDEDC, Figure 4B. IDE normally cleaves bendorphin at the Leu17-Phe18 and Phe18-Lys19 bonds [16]. The
rIDEDC mutant cleaved at these sites, but in addition cleaved at
Thr6-Ser7 plus Phe18-Lys19 and at Thr6-Ser7 plus Asn20-Ala21.
Time course experiments showed that these products could not be
detected with wild type IDE throughout the entire time course of
its reaction with b-endorphin. Additional cleavage sites in bendorphin (Met5-Thr6 and Lys19-Asn20) were previously observed
in the reaction of rIDE mutants containing substitutions of the
active site glutamate [16].
We previously reported that substrates for IDE such as
bradykinin and dynorphin B-9 act as activators of the hydrolysis
of Abz-GGFLRKHGQ-EDDnp [11]. Based on our hypothesis
that activation of IDE by activators occurs through conformational
changes transmitted from one subunit to the other, we would
predict that the monomeric rIDEDC variant would not exhibit this
activation. That this is the case is shown for bradykinin and
dynorphin B9 as the effectors, Figure 5. With wild type rIDE,
bradykinin and dynorphin B-9 activate the reaction while with
rIDEDC these peptides inhibited the reaction slightly.
Polyphosphates, including ATP and triphosphate (PPPi) also
activate the IDE dependent hydrolysis of small substrates including
Abz-GGFLRKHGQ-EDDnp [12]. The ATP binding site was
shown to be distinct from both the substrate binding site as well as
the distal site where peptide activators such as bradykinin and
dynorphin B-9 bind. We thus determined whether ATP or PPPi
[12] were capable of increasing the rate of the reaction of rIDEDC
with Abz-GGFLRKHGQ-EDDnp. As shown in Figure 6 neither
ATP nor PPPi could activate the reaction of rIDEDC under
conditions in which the reaction of the wild type enzyme was
increased more than 100 fold. Interaction of the ATP analog
TNP-ATP with IDE can be followed by measuring the change in
fluorescence that occurs upon binding [17]. We therefore
compared the fluorescence spectra of TNP-ATP in the presence
and absence of the monomeric IDE variant. As shown in Figure 7,
the monomeric IDE variant produces an increase in TNP-ATP
fluorescence and a slight shift in the fluorescence maximum to a
lower wavelength, characteristic of TNP binding [17]. However
PLoS ONE | www.plosone.org
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Figure 4. HPLC chromatograms showing the cleavage of Ab1–40 and b-endorphin by IDE and IDEDC. (Top) Reaction mixtures containing
10 mM Ab1–40 in 50 mM Tris-HCl, pH 7.4 (curve A) were incubated with 100 ng of IDE for 5 min (curve B) or 2 mg of the monomeric IDE variant for
3 hrs (curve C). The amount of enzyme and time used was chosen so that a similar fraction of substrate would be consumed by both IDE and the
monomeric IDE variant permitting a comparison of products formed at the same fraction of substrate consumed. Reaction products were separated
by gradient HPLC on a Vydac C4 reverse phase column as previously described (16). Product peaks were collected manually and identified by mass
spectrometry. Peak 1 is Ab1–14 (observed mass = 1698.72, calculated mass = 1698.72); peak 2 is Ab1–13 (observed mass = 1561.68, calculated
mass = 1561.58); peak 3 is Ab1–18 (observed mass = 2167.32, calculated mass = 2167.32); peak 4 is Ab1–13 (observed mass = 2314.50, calculated
mass = 2314.5); peak 5 is Ab1–20 (observed mass = 2461.67, calculated mass = 2461.67); peak 6 is Ab5–28 (observed mass = 1581.78, calculated
mass = 1581.78); peak 7 is Ab21–40 (observed mass = 1885.96, calculated mass = 1886.2); peak 8 is Ab20–40 (observed mass = 2033.02, calculated
mass = 2033.37); peak 9 is Ab4–40 (observed mass = 2785.50, calculated mass = 2786.29); peak 10 is Ab1–17 (observed mass = 2068.04, calculated
mass = 2068.19); peak 11 is Ab26–40 (observed mass = 1413.80, calculated mass = 1414.73); peak 12 is Ab19–33 (observed mass = 1524.76, calculated
mass = 1524.69); peak 13 is Ab14–22 (observed mass = 1118.60, calculated mass = 1118.3). Note peaks 3 and 4 are absent in the rIDEDC cleavage
products, while peaks 10 to 13 are unique to rIDEDC. Although not shown the reaction was followed from ,15% cleavage to ,90% cleavage with
similar results. (Bottom) Reaction mixtures containing 10 mM b-endorphin (bEp) in 50 mM Tris-HCl, pH 7.4 (curve A) were incubated with 50 ng of IDE
for 15 min (curve B) or 2 mg of the monomeric IDE variant for 3 hrs (curve C). Reaction conditions and product separation and identification were as in
(A) above. Peak 1 is b-endorphin 19–31 (observed mass = 1475.84, calculated mass = 1476.74); peak 2 is b-endorphin 18–31 (observed mass = 1623.91,
calculated mass = 1623.91); peak 3 is b-endorphin 1–17 with methionine oxidized to its sulfoxide (observed mass = 1874.94, calculated mass = 1875.13);
Peak 4 is b-endorphin 1–18 (observed mass = 2005.97, calculated mass = 2006.3); peak 5 is b-endorphin 7–20 (observed mass = 1590.86, calculated
mass = 1591.82); peak 6 is b-endorphin 7–18 (observed mass = 1348.70, calculated mass = 1349.54). Note peaks 5 and 6 were only observed in the
reaction with IDEDC. Although not shown the reaction was followed from ,20% cleavage to ,85% cleavage with similar results.
doi:10.1371/journal.pone.0009719.g004
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Figure 5. Effect of bradykinin and dynorphin B9 on the reaction of IDEDC and wild type IDE with Abz-GGFLRKHGQ-EDDnp. Activity
was determined in 50 mM Tris-HCl, pH 7.4 with 10 mM Abz-GGFLRKHGQ-EDDnp as substrate and the indicated concentrations of bradykinin (left) or
dynorphin B9 (right). The reactions with wild type IDE (filled squares) contained 0.25 mg of protein and with IDEDC (filled triangles) 1.25 mg of protein
was used. With wild type IDE the maximal activation produced by bradykinin varied from 4.4 to 5.4 fold, while a 15 to 30% inhibition was seen with
monomeric IDE. Similarly dynorphin B9 produced a 3.4 to 4.3 fold activation of wild type IDE, but inhibited the monomeric IDE variant 10 to 40%.
doi:10.1371/journal.pone.0009719.g005

The observation that both Ab1–40 and b-endorphin are cleaved
at unique sites by monomeric rIDE further suggests that substrate
binding is different in the monomeric enzyme. Thus interactions
between subunits in the oligomeric form of IDE likely contribute
to the conformation of the enzyme-substrate complex.
It should be noted that we can not rule out a mechanism in
which dimer contacts are required for activation to occur within a
subunit, although previous studies [11] with mixed dimers
containing one catalytically active and one catalytically inactive
subunit weigh against this alternative. It is also possible that loss of
the C-terminal 18 residues directly affects the properties of the
enzyme independent of the effect on oligomerization. Given the
tenuous attachment of these residues to the rest of the enzyme, this
possibility seems unlikely.
We find that in contrast to wild type IDE, the activity of
monomeric IDE is not increased by small peptides or by
polyphosphates. However binding of the nucleotide triphosphate
TNP-ATP does occur as shown by an increase in its fluorescence
in the presence of monomeric IDE. Thus the absence of activation
of monomeric IDE in the presence of binding can be accounted
for by the necessity of a conformational change induced by
activator binding to one subunit and transmitted to the adjacent
subunit. Alternatively or additionally the oligomeric form of IDE
might be required for proper activator binding. That this may be a

contributing factor is indicated by the observation of a smaller shift
of the fluorescence maxima of bound TNP-ATP with monomeric
IDE compared to oligomeric IDE.

Materials and Methods
Preparation of an IDE C-terminal Deletion Mutant
For construction of an IDE mutant with the C-terminal 18
amino acids deleted PCR was used to generate a 360 bp fragment
containing a stop codon, which replaced a 415 bp Pst I – Xho I
fragment from the rIDE cDNA in pFast Bac HTb.
Oligonucleotides used for preparing the deletion mutant were:
59 – TATCTGCAGAGTGCGCGAAGTACTAGG – 39
Pst I
59 – AGACTCGAGTCAGCCGCGCTTGAATTCAGT – 39
Xho I stop codon

IDE Expression and Purification
Native rIDE and its C-terminal deletion mutant, rIDEDC were
expressed in Sf9 insect cells and purified as hexahistidine fusion
proteins on HIS-select Ni-NTA agarose (Sigma) as previously
described [16,18]. This procedure generally yielded homogeneous
native rIDE, however in those instances when contaminants were
detected, anion exchange chromatography on a 1 ml MonoQ

Figure 6. Effect of ATP and PPPi on the reaction of IDEDC and wild type IDE with Abz-GGFLRKHGQ-EDDnp. Reactions contained 50 mM
Tris-HCl, pH 7.4 with 10 mM Abz-GGFLRKHGQ-EDDnp as substrate and the indicated concentrations of ATP (A) or PPPi (B). The reactions with wild
type IDE (filled squares) contained 0.25 mg of protein while the reaction with IDEDC (filled triangles) contained 1.25 mg of protein. In separate
experiments ATP increased the activity of wild type IDE 130 to 160 fold, while PPPi increased the rate 88 to 97 fold. In contrast ATP increased the rate
of the monomeric IDE variant 1.5 to 3 fold, while PPPi increased the rate 1.5 to 2.5 fold.
doi:10.1371/journal.pone.0009719.g006
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Figure 7. Binding of TNP-ATP to IDEDC. Fluorescence emission spectra of 10 mM TNP-ATP in the presence or absence of 1.5 mM of IDEDC in
50 mM Tris-HCl, pH 7.4 were recorded on a Perkin-Elmer LS 55 Luminescence spectrometer. Fluorescence spectra were recorded with a
lexc = 403 nm.
doi:10.1371/journal.pone.0009719.g007

column was used to produces enzyme of ,90% purity.
Recombinant rIDEDC did not express as well as wild type rIDE
in Sf9 cells and yielded enzyme preparations of ,50–60% purity.

Activation studies
Activation of IDE by peptides or by triphosphates was
determined by measuring their ability to increase the rate of
Abz-GGFLRKHGQ-EDDnp cleavage. Data were fit to a
hyperbolic response curve using Prism Graphpad software.

Enzyme Activity Assay
The internally quenched fluorogenic peptide Abz-GGFLRKHGQ-EDDnp was used to routinely measure IDE activity as
previously described [18]. Reaction mixtures (200 ml) contained
50 mM Tris-HCl, pH 7.4 with 10 mM Abz-GGFLRKHGQEDDnp.

Molecular weight determination
Gel filtration was performed on a Pharmacia Superdex S200
column equilibrated with 20 mM potassium phosphate buffer,
pH 7.4 and run at a flow rate of 0.4 ml/min. The eluted fractions
(1 ml) were assayed for IDE activity using Abz-GGFLRKHGQEDDnp as substrate.

Kinetic Analysis
Kinetic data were fit using Graphpad software to either a
hyperbolic substrate versus velocity response curve (v = Vmax[S]/
(KM + [S]) (Michaelis-Menten equation) or to a sigmoidal response
curve (v = Vmax[S]h/(KM + [S]h), where v is the observed rate,
Vmax is the maximal velocity, KM is the Michaelis constant, S is
the variable substrate, and h is the Hill coefficient. For reactions
with physiological peptides, a fixed concentration of b-endorphin
(10 mM) and amyloid b peptide (10 mM) was incubated with IDE
(50 ng) or IDEDC (2 mg) for 15 min to 3 hrs. The rate of peptide
cleavage was determined by following the disappearance of the
parent peptide by HPLC [16]. Product peaks were collected and
their identification determined by tandem mass spectrometry.
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